Business
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an abstract was accepted for presentation at ACR Convergence, the annual meeting of the American College of Rheumatology. The meeting, the world’s premier virtual rheumatology experience, will take place online November 10 – 14, 2022 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.\n\nTitle: Urine ALCAM is a Strong Predictor of Lupus Nephritis\nFirst Author: Dalena Chu, Associate Scientist, Equillium, Inc.\nSession Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations\nSession Type: Virtual Poster\nDate and Time: 1:00 pm – 3:00 pm ET, Sunday, November 13, 2022\nAbstract Number: 1478\n\nThe abstract highlights that levels of urinary soluble ALCAM (sALCAM) is a potential biomarker of disease severity in lupus nephritis that could be indicative of a patient’s response to treatment. Analyses are in progress to evaluate sALCAM in combination with other measures of disease severity to predict longer term disease outcomes.\n\nAbout Systemic Lupus Erythematosus (SLE) / Lupus Nephritis (LN)\n\nSystemic lupus erythematosus is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels. Lupus nephritis is a serious complication of SLE, occurring in approximately 30% – 60% of individuals with SLE. In LN, the body’s own immune system attacks the kidneys, causing inflammation and significantly reducing kidney function over time.\n\nAbout Itolizumab\n\nItolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited.\n\nAbout Equillium\n\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflamma...